The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > COMMENTARY
COMMENTARY
-
January 20, 2003
- < Special Contribution >
January 13, 2003
- BARKER ON DRUGS
December 23, 2002
- BARKER ON DRUGS (10)
November 18, 2002
- BARKER ON DRUGS (9)
October 14, 2002
- Commentary 2 articles
October 7, 2002
- Barker on Drugs (8)
September 9, 2002
- Barkers on Drugs (7)
July 29, 2002
- BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
- BARKER ON DRUGS(5)
June 3, 2002
- BARKER ON DRUGS(4)
April 22, 2002
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
- Barker on Drugs (1)
January 14, 2002
- Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…